Diffuse Intrinsic Pontine Glioma (DIPG) is a rare and aggressive brainstem tumor that primarily affects children aged 5 to 10. It grows in the pons, a critical area that controls vital functions like breathing and motor activity. DIPG is challenging to treat due to its location and resistance to standard chemotherapy. In India, DIPG treatment including imaging, radiation therapy, and supportive care typically costs between $6,000–$15,000, making it more accessible for international families seeking expert pediatric care.
DIPG is a malignant tumor located in the pons region of the brainstem, an area that controls essential bodily functions like heartbeat, breathing, eye movement, and balance. Because the tumor infiltrates this sensitive area, surgical removal is not possible, and treatment focuses on symptom control and slowing disease progression.
DIPG accounts for 10–15% of all childhood brain tumors and is one of the most difficult pediatric cancers to manage due to its location and aggressive nature.
DIPG is classified as a high-grade glioma, meaning it grows quickly and invades surrounding tissues. It arises from glial cells, which support and protect neurons. DIPG is "diffuse" because it spreads widely within the pons, and "intrinsic" because it originates from within the brainstem tissue.
Modern understanding also identifies the H3 K27M gene mutation in many DIPG cases, which has led to newer treatment strategies and clinical trials.
Traditionally, DIPG was diagnosed based on location and imaging. However, advances in molecular biology now allow for classification based on genetic mutations, including:
While DIPG is not formally "staged" like other cancers, its progression is rapid, and prognosis is closely linked to symptom onset and molecular features.
The exact cause of DIPG is unknown, but researchers believe it is not inherited or caused by lifestyle. Current evidence suggests:
DIPG is rare, occurring in fewer than 300 children per year globally.
Symptoms develop rapidly over weeks and may include:
Due to its fast progression, any of these signs in children should be evaluated urgently.
The gold standard for diagnosis. It shows characteristic swelling and infiltration of the pons.
Assesses motor skills, eye movement, and cranial nerve function.
Historically avoided due to risk, but now performed in specialized centers for molecular analysis and clinical trials.
Without treatment, DIPG typically leads to neurological deterioration within weeks to months. Median survival is around 9–12 months, though a small percentage of patients may live longer, especially with access to targeted or experimental therapies.
In rare cases, biopsy or ventricular shunt placement may be needed.
Early diagnosis allows for:
India is emerging as a hub for pediatric neuro-oncology, offering:
Dr. Ankur Bahl is a renowned oncologist known for:
|
Treatment Component |
Estimated Cost (USD) |
|
MRI & Initial Diagnostics |
$400 – $800 |
|
Radiation Therapy (entire course) |
$2,500 – $5,000 |
|
Hospital Stay (if needed) |
$100 – $300/day |
|
Supportive Care & Rehab |
$1,000 – $2,500 |
|
Total Estimate (3–6 months) |
$6,000 – $15,000 |
India offers 70–80% savings compared to the U.S. or Europe, with high-quality care and advanced technology.
Median survival: ~9–12 months with radiation.
Some children survive longer with newer treatments and strong supportive care.
Follow-up includes:
These stories inspire hope while contributing to ongoing research.
Diffuse Intrinsic Pontine Glioma (DIPG) is a heartbreaking diagnosis, but families do not have to face it alone. In India, compassionate care, modern radiation technologies, and cost-effective support systems offer comfort, dignity, and hope in the face of a difficult journey. Under the expert guidance of professionals like Dr. Ankur Bahl, India continues to be a beacon of advanced, empathetic pediatric cancer care.
Reach out today for a personalized consultation and cost estimate.